Tilray (NASDAQ:TLRY) Stock Price Up 0.8% - What's Next?

Tilray Inc (NASDAQ:TLRY - Get Free Report) traded up 0.8% during mid-day trading on Friday . The company traded as high as $1.48 and last traded at $1.47. 15,046,320 shares were traded during mid-day trading, a decline of 57% from the average session volume of 34,716,125 shares. The stock had previously closed at $1.46.

Wall Street Analysts Forecast Growth

Separately, Roth Mkm reduced their price target on Tilray from $2.00 to $1.75 and set a "neutral" rating on the stock in a research report on Friday, October 11th.

Tilray Price Performance

The business has a fifty day simple moving average of $1.40 and a 200-day simple moving average of $1.63. The stock has a market capitalization of $1.31 billion, a P/E ratio of -5.37 and a beta of 2.09. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.57 and a current ratio of 2.47.

Tilray (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings data on Thursday, October 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.04). Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The company had revenue of $200.00 million for the quarter, compared to analysts' expectations of $218.70 million. During the same quarter in the prior year, the firm earned ($0.10) EPS. The business's revenue was up 13.0% on a year-over-year basis. Sell-side analysts expect that Tilray Inc will post -0.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Tilray

In other Tilray news, CFO Carl A. Merton bought 26,000 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were bought at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the acquisition, the chief financial officer now directly owns 26,000 shares of the company's stock, valued at approximately $35,360. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.87% of the company's stock.

Institutional Trading of Tilray

Several institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its holdings in Tilray by 1,314.1% during the third quarter. BNP Paribas Financial Markets now owns 1,819,494 shares of the company's stock worth $3,202,000 after buying an additional 1,690,827 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Tilray during the 3rd quarter worth approximately $1,348,000. Bank of Montreal Can raised its holdings in shares of Tilray by 19.6% in the 2nd quarter. Bank of Montreal Can now owns 2,169,100 shares of the company's stock worth $3,622,000 after purchasing an additional 355,778 shares during the period. XTX Topco Ltd lifted its stake in Tilray by 1,079.7% in the third quarter. XTX Topco Ltd now owns 281,504 shares of the company's stock valued at $495,000 after purchasing an additional 257,641 shares during the last quarter. Finally, Barclays PLC grew its holdings in Tilray by 600.4% during the third quarter. Barclays PLC now owns 204,144 shares of the company's stock valued at $359,000 after purchasing an additional 174,997 shares during the period. Institutional investors own 9.35% of the company's stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.